Literature DB >> 1491401

The nature of antiphospholipid antibodies.

J Rauch1, A S Janoff.   

Abstract

Despite the striking clinical manifestations associated with antiphospholipid antibodies (aPL) the role of these autoantibodies in disease and the nature of their true "inducing" and "target" antigens remain elusive. To address these issues, we investigated the immunogenic potential of phospholipid structures. To date, phospholipid immunogens have included hexagonal (II) forms of phosphatidylethanolamine and mixtures of apolipoprotein H (beta 2-glycoprotein I) with cardiolipin. Both hexagonal (II) phosphatidylethanolamine and the cardiolipin/apolipoprotein H mixture were capable of inducing aPL with lupus anticoagulant activity. Bilayer phosphatidylethanolamine and cardiolipin in the absence of apolipoprotein H were nonimmunogenic. Our data support our views that specific phospholipid structures are recognized by the immune system and that such structures serve as inducing and/or target antigens in the pathogenesis of aPL in vivo.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1491401

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  2 in total

1.  Beta2-glycoprotein I (beta2-GPI) mRNA is expressed by several cell types involved in anti-phospholipid syndrome-related tissue damage.

Authors:  B Caronti; C Calderaro; C Alessandri; F Conti; R Tinghino; G Palladini; G Valesini
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

2.  A human monoclonal IgA autoantibody--185/12--behaves like an autoimmune antiphospholipid antibody.

Authors:  I Yron; L Shohat; J Lahav; I P Witz; B Fisch
Journal:  Clin Exp Immunol       Date:  1994-08       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.